Your browser is no longer supported. Please, upgrade your browser.
XNCR Xencor, Inc. daily Stock Chart
Xencor, Inc.
Index- P/E- EPS (ttm)-1.45 Insider Own0.20% Shs Outstand57.27M Perf Week0.64%
Market Cap2.35B Forward P/E- EPS next Y-1.98 Insider Trans0.00% Shs Float56.29M Perf Month5.59%
Income-82.60M PEG- EPS next Q-0.61 Inst Own- Short Float6.77% Perf Quarter14.15%
Sales84.40M P/S27.83 EPS this Y135.20% Inst Trans1.08% Short Ratio12.26 Perf Half Y35.44%
Book/sh9.93 P/B4.13 EPS next Y-22.20% ROA-12.60% Target Price49.64 Perf Year6.50%
Cash/sh9.61 P/C4.26 EPS next 5Y- ROE-14.20% 52W Range19.35 - 43.90 Perf YTD19.13%
Dividend- P/FCF- EPS past 5Y23.50% ROI2.30% 52W High-6.67% Beta0.94
Dividend %- Quick Ratio8.10 Sales past 5Y75.10% Gross Margin- 52W Low111.73% ATR1.73
Employees166 Current Ratio8.10 Sales Q/Q62.40% Oper. Margin- RSI (14)55.70 Volatility3.69% 4.94%
OptionableYes Debt/Eq0.00 EPS Q/Q-21.40% Profit Margin-97.90% Rel Volume0.86 Prev Close40.95
ShortableNo LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume310.96K Price40.97
Recom1.80 SMA202.31% SMA502.62% SMA20020.96% Volume266,105 Change0.05%
Mar-04-20Initiated Barclays Underweight $28
Feb-25-20Upgrade Guggenheim Neutral → Buy $43
Jan-30-20Initiated RBC Capital Mkts Outperform $44
Nov-20-19Resumed Guggenheim Neutral
Aug-07-19Downgrade Raymond James Outperform → Mkt Perform
Aug-07-19Downgrade Guggenheim Buy → Neutral
Jun-13-19Initiated Mizuho Buy
Apr-12-19Initiated Guggenheim Buy
Mar-27-19Initiated Berenberg Buy $45
Mar-15-19Initiated Raymond James Outperform
Sep-10-18Resumed BTIG Research Buy $56
Mar-28-18Resumed Leerink Partners Outperform $36
Mar-02-17Reiterated Wedbush Outperform $27 → $33
Mar-02-17Initiated Instinet Neutral $21
Oct-04-16Initiated Piper Jaffray Overweight
Dec-22-15Initiated Canaccord Genuity Buy $20
Aug-05-15Reiterated MLV & Co Buy $22 → $29
Feb-12-15Reiterated Oppenheimer Outperform $22 → $28
Jan-28-15Reiterated MLV & Co Buy $18 → $22
Jul-11-14Initiated Oppenheimer Outperform $22
Nov-12-20 04:01PM  
Nov-11-20 04:02PM  
Nov-10-20 07:51AM  
Nov-09-20 08:00AM  
Nov-06-20 03:30PM  
Nov-05-20 05:45PM  
Nov-04-20 10:15AM  
Oct-29-20 04:01PM  
Oct-14-20 05:00PM  
Oct-13-20 12:03PM  
Oct-02-20 09:00AM  
Sep-23-20 12:09PM  
Sep-09-20 04:01PM  
Sep-03-20 08:01AM  
Aug-05-20 04:01PM  
Aug-04-20 05:25PM  
Jul-31-20 10:49PM  
Jul-28-20 05:01PM  
Jul-14-20 11:14AM  
Jul-08-20 08:01AM  
Jun-30-20 11:35PM  
Jun-22-20 09:06AM  
Jun-08-20 01:48PM  
May-26-20 04:01PM  
May-15-20 12:01AM  
May-13-20 05:00PM  
May-11-20 01:35PM  
May-08-20 09:30PM  
May-07-20 04:01PM  
Apr-30-20 04:01PM  
Apr-13-20 03:49PM  
Apr-07-20 02:10PM  
Mar-26-20 08:23AM  
Mar-25-20 04:01PM  
Mar-02-20 02:55PM  
Feb-28-20 07:43AM  
Feb-26-20 11:59AM  
Feb-24-20 05:45PM  
Feb-18-20 08:01AM  
Feb-17-20 12:30PM  
Feb-06-20 04:01PM  
Feb-05-20 10:28AM  
Jan-09-20 05:10PM  
Jan-08-20 12:08PM  
Dec-30-19 10:13AM  
Dec-20-19 08:01AM  
Dec-18-19 08:01AM  
Dec-14-19 08:05PM  
Dec-09-19 10:00AM  
Nov-19-19 12:58PM  
Nov-18-19 11:48PM  
Nov-13-19 04:01PM  
Nov-06-19 09:00AM  
Nov-05-19 06:05PM  
Oct-29-19 04:01PM  
Oct-28-19 10:31AM  
Oct-21-19 12:55PM  
Oct-10-19 03:34PM  
Sep-26-19 04:01PM  
Sep-10-19 04:01PM  
Aug-23-19 10:00AM  
Aug-22-19 09:15PM  
Aug-21-19 06:53AM  
Aug-08-19 11:13AM  
Aug-06-19 06:05PM  
Aug-01-19 04:01PM  
Jul-30-19 04:01PM  
Jul-12-19 06:16PM  
Jul-09-19 12:52PM  
Jul-02-19 08:58AM  
Jun-27-19 08:01AM  
Jun-26-19 10:12AM  
Jun-24-19 06:00PM  
Jun-08-19 09:14AM  
Jun-03-19 08:01AM  
May-23-19 08:01AM  
May-10-19 09:23AM  
May-09-19 04:43PM  
May-08-19 04:01PM  
May-06-19 08:01AM  
May-02-19 04:01PM  
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; Amgen Inc.; and Catalent Pharma Solutions LLC., as well as a clinical collaboration with MorphoSys AG and Incyte Corporation to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kuch John JSr. Vice President & CFOJun 12Option Exercise11.0510,000110,50090,602Jun 16 08:45 PM
STAFFORD JOHN S III10% OwnerApr 06Sale27.43644,77117,685,509606,005Apr 08 04:26 PM
Ronin Capital, LLC10% OwnerMar 20Sale29.8950,7701,517,6425,012,430Mar 23 05:37 PM
Ronin Capital, LLC10% OwnerMar 19Sale28.2326,800756,5935,063,200Mar 23 05:37 PM
STAFFORD JOHN S III10% OwnerJan 08Sale36.6860,8762,232,9321,250,776Jan 08 05:28 PM
STAFFORD JOHN S III10% OwnerJan 07Sale35.956,047217,3901,311,652Jan 08 05:28 PM
STAFFORD JOHN S III10% OwnerJan 06Sale35.8158,8622,107,9071,317,699Jan 08 05:28 PM
STAFFORD JOHN S III10% OwnerDec 26Sale40.044,119164,9251,376,561Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 24Sale39.7143,7201,736,1211,380,680Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 23Sale39.5191,6773,622,3421,424,400Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 20Sale39.3973,4232,892,1321,516,077Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 11Sale38.6837,9511,467,9451,589,500Dec 11 06:48 PM
STAFFORD JOHN S III10% OwnerDec 10Sale40.13252,22510,121,7891,627,451Dec 11 06:48 PM
STAFFORD JOHN S III10% OwnerDec 09Sale41.64120,3245,009,7501,879,676Dec 11 06:48 PM
AWRE Aware, Inc. daily Stock Chart
Aware, Inc.
Index- P/E- EPS (ttm)-0.63 Insider Own23.70% Shs Outstand21.48M Perf Week13.92%
Market Cap66.49M Forward P/E- EPS next Y- Insider Trans0.70% Shs Float12.66M Perf Month18.25%
Income-13.50M PEG- EPS next Q- Inst Own36.40% Short Float0.39% Perf Quarter14.34%
Sales10.30M P/S6.46 EPS this Y-779.00% Inst Trans0.70% Short Ratio1.38 Perf Half Y-12.39%
Book/sh2.20 P/B1.41 EPS next Y- ROA-24.40% Target Price- Perf Year-11.65%
Cash/sh1.98 P/C1.57 EPS next 5Y- ROE-26.60% 52W Range2.02 - 3.88 Perf YTD-7.44%
Dividend- P/FCF- EPS past 5Y-31.50% ROI-17.50% 52W High-19.82% Beta0.08
Dividend %- Quick Ratio9.50 Sales past 5Y-12.40% Gross Margin93.80% 52W Low53.96% ATR0.14
Employees71 Current Ratio9.50 Sales Q/Q-16.70% Oper. Margin-89.30% RSI (14)73.88 Volatility6.19% 5.50%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.79 Prev Close3.08
ShortableYes LT Debt/Eq0.00 EarningsOct 27 AMC Payout- Avg Volume35.61K Price3.11
Recom- SMA2015.11% SMA5015.65% SMA2007.42% Volume27,971 Change0.95%
May-09-08Downgrade Merriman Curhan Ford Buy → Neutral
May-01-07Initiated Merriman Curhan Ford Buy
Mar-23-07Initiated MDB Capital Group Buy $7.50
Nov-17-20 08:30AM  
Nov-12-20 09:45AM  
Nov-10-20 11:13AM  
Nov-05-20 06:27AM  
Oct-27-20 04:05PM  
Oct-06-20 09:00AM  
Sep-28-20 04:40PM  
Sep-15-20 03:05PM  
Sep-06-20 10:41AM  
Sep-03-20 09:05AM  
Jul-08-20 11:35AM  
May-04-20 11:05AM  
Apr-28-20 04:08PM  
Mar-30-20 04:05PM  
Mar-19-20 06:16AM  
Feb-11-20 04:07PM  
Dec-20-19 04:29PM  
Nov-19-19 11:05AM  
Oct-29-19 04:05PM  
Oct-17-19 12:19PM  
Oct-01-19 04:05PM  
Sep-19-19 04:05PM  
Sep-02-19 03:05PM  
Jul-30-19 04:05PM  
Jul-17-19 12:19PM  
May-24-19 01:22PM  
Apr-30-19 06:18PM  
Apr-03-19 03:12PM  
Feb-25-19 01:34PM  
Feb-19-19 11:48AM  
Feb-12-19 05:37PM  
Jan-18-19 09:40AM  
Nov-23-18 07:40AM  
Oct-23-18 04:44PM  
Sep-24-18 11:47AM  
Sep-06-18 03:18PM  
Jul-30-18 06:45PM  
Jul-24-18 05:41PM  
Jun-28-18 02:37PM  
Apr-24-18 04:56PM  
Mar-19-18 07:10AM  
Feb-22-18 04:49PM  
Dec-27-17 11:00AM  
Dec-13-17 12:45PM  
Nov-30-17 01:28PM  
Nov-20-17 11:43AM  
Nov-08-17 08:11AM  
Nov-07-17 09:42AM  
Oct-24-17 05:23PM  
Oct-19-17 09:21AM  
Oct-17-17 09:34AM  
Aug-24-17 02:59PM  
Aug-01-17 11:11AM  
Jul-25-17 05:22PM  
Jul-11-17 02:05PM  
Jun-19-17 02:58PM  
May-18-17 01:32PM  
May-02-17 03:42PM  
May-01-17 10:29AM  
Apr-25-17 04:49PM  
Apr-24-17 03:15PM  
Apr-05-17 04:22PM  
Mar-09-17 04:16PM  
Mar-08-17 02:14PM  
Mar-01-17 04:13PM  
Feb-16-17 01:04PM  
Feb-14-17 02:37PM  
Feb-10-17 09:40AM  
Feb-09-17 02:40PM  
Feb-07-17 04:45PM  
Feb-01-17 09:45AM  
Jan-19-17 12:22PM  
Dec-29-16 01:30PM  
Dec-16-16 11:10AM  
Dec-02-16 11:52AM  
Nov-16-16 12:42PM  
Oct-28-16 02:49PM  
Oct-27-16 10:48AM  
Oct-25-16 04:58PM  
Aware, Inc. provides software and services for the biometrics industry in the United States, the United Kingdom, Brazil, and internationally. It offers biometrics software products, including biometric search and matching software development kits (SDKs), biometric enrollment SDKs and application program interfaces (APIs), identity text analytics SDK A Inquire, biometric services platform A BioSP, and cluster-based matching platform A Astra; and integrated solutions comprising Knomi, AwareABIS, WebEnroll, and Indigo, as well as biometric applications that enable various functions in biometrics systems, such as enrollment, analysis, and processing of biometric images and data on workstations or mobile devices; integration of peripheral biometric capture devices; centralized workflow, transaction processing, and subsystem integration; matching of biometric samples against biometric databases to authenticate or verify identities; and analysis and processing of text-based identity data. The company also provides imaging products for medical applications, such as JPEG2000 product to compress, store, and display images, as well as software maintenance services. In addition, it offers software engineering services comprising project planning and management; system design; software design, development, customization, configuration, and testing; and software integration and installation. The company's software products are used in government and commercial biometrics systems to identify or authenticate people. It sells its biometrics software products and services through systems integrators, OEMs, value added resellers, and directly to end user customers. Aware, Inc. was founded in 1986 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Eckel Robert ACEO and PresidentNov 18Buy2.7910,00027,895117,422Nov 20 04:46 PM
Barcelo David BrianChief Financial OfficerNov 18Buy2.7415,00041,15010,000Nov 20 04:46 PM
Mungovan Robert MChief Commercial OfficerOct 01Option Exercise0.0010,0000123,780Oct 08 04:22 PM
Eckel Robert ACEO and PresidentSep 19Option Exercise0.0020,0000107,422Sep 23 06:10 PM
STAFFORD JOHN S IIIDirectorAug 19Buy2.815,00014,04515,000Aug 19 04:45 PM
STAFFORD JOHN S IIIDirectorAug 17Buy2.725,00013,60010,000Aug 19 04:45 PM
STAFFORD JOHN S IIIDirectorJul 01Option Exercise0.005,00005,000Jul 06 11:42 AM
Eckel Robert ASee RemarksJun 30Option Exercise0.0025,000087,422Jul 02 04:42 PM
Mungovan Robert MChief Commercial OfficerJun 30Option Exercise0.0012,5000113,780Jul 02 04:42 PM
Connolly Brian DDirectorJun 30Option Exercise0.005,0000100,000Jul 02 04:42 PM
Faubert Peter R.DirectorJun 30Option Exercise0.005,00005,000Jul 02 04:42 PM
Johnstone Brent PDirectorJun 30Option Exercise0.0010,000094,166Jul 02 04:42 PM
Lazzouni MohamedChief Technical OfficerJun 30Option Exercise0.0012,500012,500Jul 02 04:42 PM
Barcelo David BrianChief Financial OfficerJun 30Option Exercise0.0010,000010,000Jul 02 04:40 PM
Eckel Robert ACEO and PresidentMay 08Buy2.725,00013,60462,422May 11 04:05 PM
Eckel Robert ACEO and PresidentMay 07Buy2.6310,00026,26157,422May 11 04:05 PM
Ronin Capital, LLC10% OwnerMar 16Buy2.5520,62152,4804,621,368Mar 16 05:17 PM
Ronin Capital, LLC10% OwnerMar 13Buy2.699,56525,7004,600,747Mar 16 05:17 PM
Ronin Capital, LLC10% OwnerMar 12Buy2.6514,00037,0584,591,182Mar 16 05:17 PM
Ronin Capital, LLC10% OwnerJan 02Option Exercise0.005,00004,577,182Jan 03 05:17 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.